Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Geron Corporation    GERN

Delayed Quote. Delayed  - 09/30 10:00:00 pm
2.26 USD   +2.73%
09/21 JOHNSON & JOHNS : JNJ) Janssen Builds On Partnership With Geron Corp..
09/12 Geron Provides Update on Imetelstat Trials Being Conducted by Jan..
09/11 GERON ANNOUNCES : 00 A.M. Eastern Time
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Geron Corporation : Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's Microscope

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2013 | 02:05pm CEST

LONDON, April 17, 2013 /PRNewswire/ --

In 2012, patents on several blockbuster drugs expired, leading to increasing competition from generic drug manufacturers. Major drug manufacturers are likely to see more patent expirations in 2013. As generic competition is expected to continue rising, major drug manufacturers will have to boost their product pipeline. One way of doing this will be by collaborating with or acquiring biotechnology companies that have developed or are developing potential blockbuster drugs. Among the biotechnology companies that major drug manufacturers can look at are Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corporation (NASDAQ: CELG), Incyte Corporation (NASDAQ: INCY), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Geron Corporation (NASDAQ: GERN). Biotechnology stocks ended mostly higher on Tuesday, tracking gains in the broad market. StockCall has released full comprehensive research on ARNA, CELG, INCY, SPPI, and GERN and these free technical analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Shares of Arena Pharmaceuticals Inc. edged higher on Tuesday. The stock touched an intra-day high of $8.23 before finishing the day 1.99% higher at $8.20 on volume of 3.10 million. Arena's shares have struggled so far in 2013, falling more than 9%. The stock has traded sideways over the past one month, struggling to break through $8.50 resistance level. Shares of ARNA currently have support at around $8. Free technical analysis on ARNA available by signing up at

http://www.StockCall.com/ARNA041713.pdf

Shares of Celgene Corporation rose sharply on Tuesday. The stock rose to an intra-day high of $123 before finishing the day 1.77% higher at $122.50 on volume of 2.47 million. Celgene's shares are currently trading close to their 52-week high of $124.10. The stock has had an excellent run so far in 2013, gaining more than 56%. Celgene's shares are also trading above their 50-day and 200-day moving averages. Register today and access the free research on CELG at

http://www.StockCall.com/CELG041713.pdf

Incyte Corporation's shares rose yesterday, however, the gains were limited. The stock closed 0.52% higher at $21.14 on volume of 1.22 million. Incyte's shares have fallen nearly 6% in the last three sessions. The stock has slipped below its 50-day moving average as a result of the recent selloff. The stock's MACD has also slipped below the signal line and the zero-line, which is a strong bearish signal. It is still up more than 27% so far this year. The free report on INCY can be downloaded by signing up now at

http://www.StockCall.com/INCY041713.pdf

Shares of Spectrum Pharmaceuticals Inc. gained on Tuesday, reversing some of the recent losses. The stock closed 1% higher at $7.08 on volume of 647,500 after touching an intra-day high of $7.17. Despite the gains yesterday, Spectrum's shares are still down more than 3% in the last three trading sessions. The stock is currently trading well below its 50-day and 200-day moving averages. Shares of SPPI currently face stiff resistance at around $7.50. Free report on SPPI can be accessed by registering at

http://www.StockCall.com/SPPI041713.pdf

Geron Corporation's shares fell sharply on Tuesday, extending their losses from previous trading sessions. The stock closed 1.89% lower at $1.04 on volume of 655,100, taking its losses in the last three trading sessions to over 10.30%. The company's shares have struggled so far in 2013, falling more than 26%. The stock is currently trading close to $1 support level. Register with StockCall and download the research on GERN for free at

http://www.StockCall.com/GERN041713.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GERON CORPORATION
09/21 JOHNSON & JOHNSON (NYSE : JNJ) Janssen Builds On Partnership With Geron Corporat..
09/19 GERON CORP : Entry into a Material Definitive Agreement (form 8-K)
09/12 GERON CORP : Other Events, Financial Statements and Exhibits (form 8-K)
09/12 Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
09/11 GERON ANNOUNCES CONFERENCE CALL ON S : 00 A.M. Eastern Time
08/25 GERON CORP : Other Events, Financial Statements and Exhibits (form 8-K)
08/04 GERON : reports 2Q loss
08/03 GERON CORP : Results of Operations and Financial Condition, Financial Statements..
08/03 GERON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
08/03 Geron Corporation Reports Second Quarter 2016 Financial Results and Recent Ev..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/19 As I Predicted, Cash-Rich Geron Optimizes Dosage In Myelofibrosis Trial
09/19 Geron inks license deal with Janssen Pharma valued up to $80M
09/15 GERON : Uncertainties Abound In Imetelstat Clinical Trial
09/14 BIOTECH FORUM DAILY DIGEST : Rocky Trading To Begin Week. Mylan In The News. Spo..
09/12 Midday Gainers / Losers